Spectrum Pharmaceuticals SPPI and Onxeo S.A. OXNXF today jointly announced the
results from their Phase 1 combination trial of belinostat (Beleodaq®)
with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and
Prednisone) chemotherapy regimen as first-line treatment for newly
diagnosed peripheral T-cell lymphoma (PTCL). Beleodaq® is a
histone deacetylase (HDAC) inhibitor that received accelerated approval
by the U.S. Food and Drug Administration (FDA) for the treatment of
relapsed or refractory PTCL in July 2014.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in